Epigenetic Reprogramming Sensitizes CML Stem Cells to Combined EZH2 and Tyrosine Kinase Inhibition

Mary T. Scott(Blood Cancer UK), David Vetrie(Blood Cancer UK)
Cancer Discovery
September 14, 2016
Cited by 132


Related Papers